Trials / Completed
CompletedNCT05770895
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GS-2829 | Administered intramuscularly |
| BIOLOGICAL | GS-6779 | Administered intramuscularly |
| BIOLOGICAL | Placebo | Administered intramuscularly |
Timeline
- Start date
- 2023-04-03
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
- First posted
- 2023-03-16
- Last updated
- 2026-01-23
- Results posted
- 2026-01-23
Locations
9 sites across 2 countries: New Zealand, Taiwan
Source: ClinicalTrials.gov record NCT05770895. Inclusion in this directory is not an endorsement.